Novo Nordisk signs $1.4B oral macrocycle pact with Orbis Medicines
Orbis will use its AI-driven nGen platform to find macrocyclic candidates for cardiometabolic targets that currently require injection, with Novo taking an equity stake.
TR
By Tom Reyes · Markets Editor
Sep 17 08:29 ETSource: Blockonomi
The wire
- 01Novo Nordisk and Copenhagen-based Orbis Medicines announced a discovery and licensing deal potentially worth $1.4 billion, covering upfronts, milestones and tiered royalties; the breakdown was not disclosed.
- 02The target is converting injectable cardiometabolic therapies into oral macrocyclic peptides, extending Novo's SNAC oral delivery work acquired with Emisphere in 2020.
- 03Orbis CEO Morten Graugaard says its synthetic macrocycles have shown oral bioavailability as high as 18% in early work; no candidate, timeline or equity amount has been named.
From the source
Read at blockonomi.comNovo Nordisk (NVO) Stock: Pharma Giant Inks $1.4B Partnership With Orbis for AI-Driven Oral Therapies
On Thursday, Novo Nordisk (NVO) revealed a strategic collaboration with Danish biotechnology firm Orbis Medicines, establishing a drug discovery and licensing agreement potentially worth $1.4 billion. The initiative centers on creating oral medication options for cardiometabolic disorders.